Literature DB >> 19152440

Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer.

John M Varlotto1, Abram Recht, John C Flickinger, Laura N Medford-Davis, Ann M Dyer, Malcolm M Decamp.   

Abstract

BACKGROUND: This study assessed the impact of surgical, histopathologic and patient-related factors on the risks of local and distant recurrence and overall survival for patients with stages I through IIIA nonsmall cell lung carcinoma (NSCLC) undergoing definitive resection with or without adjuvant chemotherapy.
METHODS: This study included 373 consecutive patients treated between 2000 and 2005 who did not receive adjuvant or neoadjuvant radiotherapy, had at least 3 months of follow-up, and did not have a history of other cancers within 5 years of the diagnosis of their NSCLC. Of these, 52% had pathologic stage IA disease, 30% had stage IB, 5% had stage IIA, 8% had stage IIB and 5% had stage III disease. Forty-four patients received chemotherapy.
RESULTS: The median follow-up was 33 months. Local failure rates at 2 years, 3 years, and 5 years were 16%, 22%, and 32%, respectively; distant recurrence rates were 13%, 15%, and 21%, respectively. Multivariable analysis revealed that local recurrence was significantly associated with the presence of lymphatic or vascular invasion (LVI), the use of chemotherapy, and having diabetes; distant recurrence was significantly higher in patients with nonsquamous cell histology, those undergoing pneumonectomy, and those with more advanced TNM stage. Survival was significantly associated with age, history of myocardial infarction, performance of a pneumonectomy, histology, LVI, and the number of positive N1 lymph nodes.
CONCLUSIONS: Local recurrence was the predominant type of failure in this series. Patient with diabetes or LVI may benefit from close surveillance and aggressive therapy of asymptomatic local recurrences, especially when chemotherapy is given in addition to surgery. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19152440     DOI: 10.1002/cncr.24133

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Radiologic and nuclear medicine predictors of tumor invasiveness in patients with clinical stage IA lung adenocarcinoma.

Authors:  Masaya Tamura; Makoto Oda; Isao Matsumoto; Yosuke Shimizu; Ryuichi Waseda; Go Watanabe
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

2.  Biologic Evaluation of Diabetes and Local Recurrence in Non-Small Cell Lung Cancer.

Authors:  Xuebin Yang; Yongjun Liu; Haresh Mani; Jeffrey Olson; Gary Clawson; Carla Caruso; Richard Bruggeman; John M Varlotto; Dani S Zander; Negar Rassaei
Journal:  Pathol Oncol Res       Date:  2016-07-13       Impact factor: 3.201

3.  Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.

Authors:  Hongwei Li; Jianzhong Cao; Xiaqin Zhang; Xing Song; Weili Wang; Sufang Jia; Zhengran Li; Haixia Jia; Xing Cao; Wei Zhou; Jianhong Lian; Songye Han; Weihua Yang; Yanfen Xi; Shenming Lian; Haoxing Jing
Journal:  Clin Exp Metastasis       Date:  2016-11-25       Impact factor: 5.150

4.  Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.

Authors:  Gregory E Holt; Eckhard R Podack; Luis E Raez
Journal:  Therapy       Date:  2011-01

5.  A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.

Authors:  Jeanette L Grant; Michael C Fishbein; Long-Sheng Hong; Kostyantyn Krysan; John D Minna; Jerry W Shay; Tonya C Walser; Steven M Dubinett
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-19

6.  BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.

Authors:  Peter R Bucciarelli; Kay See Tan; Neel P Chudgar; Whitney Brandt; Joseph Montecalvo; Takashi Eguchi; Yuan Liu; Rania Aly; William D Travis; Prasad S Adusumilli; David R Jones
Journal:  J Thorac Oncol       Date:  2017-10-31       Impact factor: 15.609

Review 7.  The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.

Authors:  Sharon L I Wong; Maria B Sukkar
Journal:  Br J Pharmacol       Date:  2016-11-25       Impact factor: 8.739

8.  Risk analysis of pulmonary resection for elderly patients with lung cancer.

Authors:  Hideki Endoh; Ryohei Yamamoto; Yukitoshi Satoh; Hiroyuki Kuwano; Nobuhiro Nishizawa
Journal:  Surg Today       Date:  2012-11-04       Impact factor: 2.549

Review 9.  Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions.

Authors:  Gal Shafirstein; Athar Battoo; Kassem Harris; Heinz Baumann; Sandra O Gollnick; Joerg Lindenmann; Chukwumere E Nwogu
Journal:  Ann Am Thorac Soc       Date:  2016-02

10.  Long-term outcomes after near-infrared sentinel lymph node mapping in non-small cell lung cancer.

Authors:  Christopher S Digesu; Krista J Hachey; Denis M Gilmore; Onkar V Khullar; Hisashi Tsukada; Brian Whang; Lucian R Chirieac; Robert F Padera; Michael T Jaklitsch; Yolonda L Colson
Journal:  J Thorac Cardiovasc Surg       Date:  2017-12-14       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.